Immuron (IMRN) Total Non-Current Liabilities (2017 - 2025)
Immuron (IMRN) posted quarterly Total Non-Current Liabilities of $945.77 for Q3 2025, down 33.18% year-over-year from $1415.5 in Q3 2024, and down 98.44% quarter-over-quarter from $60570.3 in Q2 2025.
Immuron (IMRN) Total Non-Current Liabilities (2017 - 2025) Analysis & Trends
Immuron's Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $945.77 for Q3 2025.
- In Q3 2025, Total Non-Current Liabilities fell 33.18% year-over-year to $945.77; the TTM figure through Sep 2025 stood at $945.77 (down 33.18% YoY), while the FY2025 annual figure was $945.77, down 33.18% from the prior year.
- Total Non-Current Liabilities for Q3 2025 stood at $945.77, down from $60570.3 in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $125667.1 in Q2 2022, with the low at $860.99 in Q4 2023.
- The 5-year median for Total Non-Current Liabilities is $63476.0 (2024), against an average of $60271.1.
- The sharpest annual moves came in 2021 and 2023: Total Non-Current Liabilities soared 8019.92% in 2021, then slumped 99.25% in 2023.
- Immuron's Total Non-Current Liabilities stood at $26496.1 in 2021, then soared by 335.05% to $115272.5 in 2022, then plunged by 99.25% to $860.99 in 2023, then soared by 7609.97% to $66381.8 in 2024, then tumbled by 98.58% to $945.77 in 2025.
- Business Quant data shows IMRN's Total Non-Current Liabilities at $945.77 in Q3 2025, $60570.3 in Q2 2025, and $66381.8 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Immuron | 6.81 Mn | 6.78 Mn | - | 945.77 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 2, 2025 | 945.77 |
| Jun 30, 2025 | 60,570.25 |
| Dec 31, 2024 | 66,381.83 |
| Sep 9, 2024 | 1,415.46 |
| Jun 30, 2024 | 93,282.28 |
| Dec 31, 2023 | 860.99 |
| Sep 28, 2023 | 99,768.61 |
| Aug 30, 2023 | 1,522.07 |
| Jun 30, 2023 | 101,729.14 |
| Dec 31, 2022 | 115,272.50 |
| Aug 31, 2022 | 122,009.86 |
| Jun 30, 2022 | 125,667.13 |
| Dec 31, 2021 | 26,496.13 |
| Jun 30, 2021 | 27,872.92 |
| Dec 31, 2020 | 326.31 |
| Sep 1, 2020 | 41,839.00 |
| Jun 30, 2020 | 27,422.14 |
| Dec 31, 2019 | 418.39 |
| Jun 30, 2019 | 10,493.07 |
| Dec 31, 2017 | 1.83 Mn |